Report ID: SQMIG35D2191
Hemophilia Market Size, Share, Growth Analysis, By Disease(Hemophilia A, hemophilia B, and others), By Product(Recombinant Coagulation Factor Concentrates, Plasma-derived Coagulation Factor Concentrates, and others), By Therapy(As Replacement Therapy, Gene Therapy, and others), By Region - Industry Forecast 2024-2031
Report ID:
SQMIG35D2191 |
Region:
Global |
Published Date: February, 2024
Pages:
157
|
Tables:
90 |
Figures:
76
Hemophilia Market Insights
Hemophilia Market size was valued at USD 12.6 billion in 2022 and is poised to grow from USD 13.43 billion in 2023 to USD 23.39 billion by 2031, at a CAGR of 6.6% during the forecast period (2024-2031).
The market for hemophilia treatment is being driven by significant factors such as the approval of gene therapy for hemophilia treatment and the presence of numerous other candidates in different stages of development.
Additionally, there is a growing awareness of hemophilia disorders and increasing government support initiatives aimed at early detection in neonates, which are expected to contribute to the growth of the market.
According to the data published by the World Federation of hemophilia (WFH) in October 2021, hemophilia is more prevalent in males than females due to sex linkage. The survey conducted by WFH in 2020 reported a total of 209,614 individuals globally suffering from hemophilia, with 165,379 patients having type A, 33,076 patients having type B, and 11,159 patients having an unknown type. The high prevalence of the disorder has contributed to the increasing adoption of therapies and is driving the growth of the market.
US Hemophilia Market is poised to grow at a sustainable CAGR for the next forecast year.
Hemophilia Market Report Snapshots
Want to customize this report?
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATION
USA (+1) 351-333-4748
